These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37578070)

  • 1. The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countries.
    Calamia M; Abraham I
    Expert Opin Biol Ther; 2023; 23(8):653-657. PubMed ID: 37578070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A health economic guide to market access of biosimilars.
    Simoens S; Vulto AG
    Expert Opin Biol Ther; 2021 Jan; 21(1):9-17. PubMed ID: 33206021
    [No Abstract]   [Full Text] [Related]  

  • 3. The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region.
    Alkhatib NS; Halloush S; Abraham I
    Expert Opin Biol Ther; 2023; 23(8):671-677. PubMed ID: 37493610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars for breast cancer.
    Migliavacca Zucchetti B; Nicolò E; Curigliano G
    Expert Opin Biol Ther; 2019 Oct; 19(10):1015-1021. PubMed ID: 31248290
    [No Abstract]   [Full Text] [Related]  

  • 5. Biosimilars in Oncology in the United States: A Review.
    Nabhan C; Parsad S; Mato AR; Feinberg BA
    JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International Society of Oncology Pharmacy Practitioners global position on the use of biosimilars in cancer treatment and supportive care.
    Frazer MB; Bubalo J; Patel H; Siderov J; Cubilla M; De Lemos M; Dhillon H; Harchowal J; Kuchonthara N; Livinalli A; Macedo R; Mwangi W; Nomura H; O'Connor S; Patterson M; Seadi Torriani M; Yim B; Chan A; Foreman E
    J Oncol Pharm Pract; 2020 Apr; 26(3_suppl):3-10. PubMed ID: 32268831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities.
    Morin S; Segafredo G; Piccolis M; Das A; Das M; Loffredi N; Larbi A; Mwamelo K; Villanueva E; Nobre S; Burrone E
    Lancet Glob Health; 2023 Jan; 11(1):e145-e154. PubMed ID: 36455593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars: A Multidisciplinary Perspective.
    Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
    Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Japanese Regulatory Systems for Generics and Biosimilars.
    Kuribayashi R; Sawanobori K
    J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries.
    Muhsen IN; Hashmi SK; Niederwieser D; Kroeger N; Agrawal S; Pasquini MC; Atsuta Y; Ballen KK; Seber A; Saber W; Kharfan-Dabaja MA; Rasheed W; Okamoto S; Khera N; Wood WA; Koh MBC; Greinix H; Kodera Y; Szer J; Horowitz MM; Weisdorf D; Aljurf M
    Bone Marrow Transplant; 2020 Apr; 55(4):698-707. PubMed ID: 31484992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
    Yoo DH
    Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America.
    Scheinberg M; Pineda C; Castañeda-Hernández G; Zarbá JJ; Damião A; Arantes LH; Jacobs I
    MAbs; 2018; 10(6):827-842. PubMed ID: 30156950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.
    Inotai A; Prins CPJ; Csanádi M; Vitezic D; Codreanu C; Kaló Z
    Expert Opin Biol Ther; 2017 Aug; 17(8):915-926. PubMed ID: 28650704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Market diffusion of biosimilars in off-patent biologic drug markets across Europe.
    Böhm AK; Steiner IM; Stargardt T
    Health Policy; 2023 Jun; 132():104818. PubMed ID: 37086662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars in the United States: Emerging Issues in Litigation.
    Wong AY; Rumore MM; Chan AW
    BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of generic medicines and biosimilars in oncology in low-income countries.
    Renner L; Nkansah FA; Dodoo AN
    Ann Oncol; 2013 Sep; 24 Suppl 5():v29-32. PubMed ID: 23975702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab biosimilars.
    Vital EM; Kay J; Emery P
    Expert Opin Biol Ther; 2013 Jul; 13(7):1049-62. PubMed ID: 23600760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars: biologics that meet patients' needs and healthcare economics.
    McCamish M; Yoon W; McKay J
    Am J Manag Care; 2016 Sep; 22(13 Suppl):S439-S442. PubMed ID: 28719221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.